Clinical OMICS

MAY-JUN 2018

Healthcare magazine for research scientists, labs, pathologists, hospitals, cancer centers, physicians and biopharma companies providing news articles, expert interviews and videos about molecular diagnostics in precision medicine

Issue link:

Contents of this Issue


Page 22 of 51 May/June 2018 Clinical OMICs 21 microsatellite instability (MSI) and tumor mutational bur- den (TMB) using DNA isolated from formalin-fixed paraffin embedded tumor tissue specimens. "As the FDA moves toward biomarker driven drug approvals that are tumor agnostic, like pembrolizumab [Merck & Co.'s cancer immunotherapy Keytruda] with MSI, having a test that is FDA approved, is mapped to a broad range of companion diagnostics, interrogates the entire cancer genome and provides TMB and MSI scores on every patient report, could have a dramatic impact on clinical care," said Gary Martucci, senior vice president, reimburse- ment and payer strategies at Foundation Medicine. FoundationOne CDx became commercially available on March 30 at a list price of $5,800. For Medicare beneficia- ries meeting NCD criteria, there is currently no anticipated co-pay or deductible amounts. CMS coverage also includes beneficiaries that are enrolled in Medicare Advantage plans. Depending on a member 's plan, they may be subject to a co-pay or deductible. But for those patients, some may be eligible for Foundation Medicine's FoundationAccess pro- gram to assist with out-of-pocket expenses, Martuccis noted. Automatic Approvals FoundationOne CDx is among four NGS cancer tests that received FDA approval or clearance as an in vitro compan- ion diagnostic, and thus automatically approved for cover- age under the final NCD. The other three: • Foundation Medicine's FoundationFocus CDxBRCA, designed to detect tumor BRCA1 and BRCA2 muta- tions, germline and somatic, in ovarian cancer. CDx- BRCA has FDA approval as a companion diagnostic assay for Clovis Oncology's Rubraca (rucaparib), a poly ADP-ribose polymerase (PARP) inhibitor indi- cated for advanced ovarian cancer. • Illumina's Praxis Extended RAS Panel, approved for use with the company's MiSeqDx System to help clinicians identify patients eligible for treatment of metastatic colorectal cancer with Amgen's Vectibix (panitumumab). • Thermo Fisher Scientific's Oncomine Dx Target Test, designed to detect 368 variants in 23 cancer-associ- ated genes clinically associated with non-small cell (continued on next page) Foundation Medicine Caris Life Sciences

Articles in this issue

Links on this page

Archives of this issue

view archives of Clinical OMICS - MAY-JUN 2018